FMP
X4 Pharmaceuticals, Inc.
XFOR
NASDAQ
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
3.26 USD
-0.03 (-0.92%)
Historical Prices
From:
To:
About
ceo
Dr. Paula Ragan Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.x4pharma.comexchange
NASDAQ
Description
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the t...
CIK
0001501697
ISIN
US98420X1037
CUSIP
98420X202
Address
61 North Beacon Street
Phone
857 529 8300
Country
US
Employee
143
IPO Date
Nov 16, 2017
Financial Statement
Earnings
XFOR Financial Summary
CIK
0001501697
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
98420X202
ISIN
US98420X1037
Country
US
Price
3.26
Beta
0.73
Volume Avg.
82.28k
Market Cap
18.87M
Shares
-
52-Week
3.05-34.2
DCF
-0.11
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
1.55
P/B
-
Website
https://www.x4pharma.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest XFOR News
Andrew Wynn
Apr 25, 2025
X4 Pharmaceuticals' Strategic Moves and Financial Health
X4 Pharmaceuticals, trading on Nasdaq under the symbol XFOR, is a biopharmaceutical company focused on developing treatments for rare immune system diseases. The company is known for its drug mavorixafor, marketed as XOLREMDI® in the U.S., and is actively conducting a Phase 3 clinical trial called 4WARD. This trial targets chronic neutropenic disorders, showcasing X4's commitment to innovative healthcare solutions. Recently, X4 announced inducement awards for new employees under its 2019 Induce...
Seeking Alpha
Aug 10, 2024
X4 Pharmaceuticals, Inc. (XFOR) Q2 2024 Earnings Call Transc...
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET Company Participants Dan Ferry - IR Paula Ragan - CEO Adam Mostafa - CFO Mark Baldry - CCO Conference Call Participants David Bautz - Zacks Small-Cap Research Stephen Willey - Stifel Leah Cann - Brookline Capital Markets RK - H.C. Wainwright Ed Tenthoff - Piper Sandler Kristen Kluska - Cantor Operator Good morning, everyone, and welcome to X4 Pharmaceuticals Second Quarter 2024 Earnings Conference C...
Seeking Alpha
Jul 2, 2024
X4 Pharmaceuticals: Catch The Falling Knife After Propitious...
X4 Pharmaceuticals, Inc. stock price dropped due to the discontinuation of Phase II study for chronic neutropenia, but the potential market for mavorixafor is substantial. X4 Pharmaceuticals is targeting rare diseases with mavorixafor, approved for WHIM syndrome, and moving forward with a Phase III trial for CN. X4 Pharmaceuticals has the potential for significant growth with mavorixafor addressing multiple rare diseases, but faces risks including FDA approval and market penetration.
GlobeNewsWire
Apr 30, 2024
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Re...
BOSTON, April 30, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the first quarter ended March 31, 2024 and providing corporate updates on Tuesday, May 7, 2024.
Reuters
Apr 29, 2024
US FDA approves X4 Pharmaceuticals' drug for immunodeficienc...
The U.S. FDA has approved X4 Pharmaceuticals' drug to treat a rare genetic immunodeficiency disease, the company said on Monday.
GlobeNewsWire
Apr 1, 2024
X4 Pharmaceuticals to Participate in Upcoming April Investor...
BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will be participating in the upcoming Needham 23rd Annual Healthcare Conference being held virtually from April 8-11, 2024, and the Piper Sandler Spring Biopharma Symposium being held in Boston from April 16-17, 2024.
GlobeNewsWire
Mar 12, 2024
X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 20...
BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the fourth-quarter and full year ended December 31, 2023 and providing corporate updates on Thursday, March 21, 2024.
Seeking Alpha
Dec 13, 2023
X4: Dip Following Mixed Results In Chronic Neutropenia Indic...
X4 Pharmaceuticals has dipped considerably following updated results presented in ASH suggesting that mavorixafor may not be effective as monotherapy in chronic neutropenia (excluding WHIM). Mavorixafor will likely still have a role in chronic neutropenia as add-on to G-CSF. Mavorixafor can enable reductions in G-CSF dosing, which can improve tolerability and is meaningful for patients. FDA has granted priority review for mavorixafor in WHIM, with a PDUFA date of April 30, 2024, and a potential ...
